Biotechnology company Novavax Inc. allegedly misled investors about how soon its Covid-19 vaccine would be ready for emergency-use authorization from the FDA, a new lawsuit said.
The Gaithersburg, Md.-based company overstated its manufacturing capabilities and downplayed issues that led to repeated delays of its filing with the Food and Drug Administration, according to a Nov. 12 shareholder complaint in the U.S. District Court for the District of Maryland.
The company’s 2020 10-K filing claimed that it planned to file for FDA emergency-use authorization in the second quarter of this year, according to the complaint.
A series of news reports and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.